 phase II studi piritrexim combin methotrex recurr metastat head neck cancer patient recurr and/or metastat head neck cancer methotrex mtx piritrexim ptx treatment schedul intraven IV mtx day oral ptx day cours day dose escal subsequ cours grade toxic patient evalu respons confid interv partial respons PR stabl diseas progress diseas respons patient region lymph node measur diseas median time progress patient month median surviv month regimen mild toxic cycl major patient dose escal subsequ cycl possibl high percentag patient overal respons rate surviv figur phase II trial disappoint dose schedul trial suboptim low incid moder sever toxic addit evalu combin drug aggress schedul